The takeaway
Corcept Therapeutics Incorporated shows a pronounced seasonal pattern over 10 years of data — strongest in May (+7.7%) and softest in December (−7.8%).
Right now
In July, the stock has risen 60% of years, averaging +2.2% — essentially in line with the S&P 500.
The full picture
Corcept Therapeutics Incorporated's most dependable month has been May, higher in 7 of 10 years; December has been its least reliable, up just 20% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 | ||||||||||||
| 2017 | ||||||||||||
| 2016 |
Month by month
The stock's clearest edge over the S&P 500 lands in March (+11.7 pts); it has trailed the market most in December (−8.8 pts).
“vs S&P” is Corcept Therapeutics Incorporated’s average for a month minus the S&P 500’s average for that same month — isolating Corcept Therapeutics Incorporated’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, May has closed higher 60% of the time versus 70% across the last 10 years — the pattern is weakening.
Figures are the typical (median) May return and how often it rose — the last 5 years versus the last 10(the heatmap’s default window). This verdict stays anchored to that 10-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
This is a stock you can almost set a calendar by, and May is the anchor — it has closed higher in 7 of 10 Mays, the steadiest beat on its year.
The strength looks broad-based rather than freakish: its average (+7.7%) and median (+9.1%) sit close together, so no single blow-out year is flattering the figure. That reliability comes with real swings, mind — even May ranges by 13.9% from year to year, so any single year can land far from the average. Better still, that strength is the stock's own and not just a buoyant market — May has outpaced the S&P 500 by +6.9 points on average. Few peers keep such company in May — the typical stock clears it just 55% of the time.
May anchors a run, too: the May-through-September window has been the stock's reliable season. At the other end of the calendar, December has been the soft spot — the weakest of 3 months that average a loss (−7.8%), and the edge isn't year-round — the stock has trailed the S&P 500 in December, April, and October. Its roughest month on record was a −56.4% December in 2025 — a reminder of how hard even a seasonal name can fall.
The pattern has softened of late, May's last five years slipping below its longer-run record.
For a stock this dependable in May, the sharper question is the rest of the year — outside its strong stretch, the calendar gives far less to lean on. With returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (May), its worst (December), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2016 its best month (May, +7.7%) has run well ahead of its worst (December, −7.8%) — the heatmap above shows how steady that gap has been year to year.
May has been the strongest, averaging +7.7% and closing higher in 7 of 10 years since 2016.
It's the weakest, averaging −7.8% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade